Biolegend, 135305, PE anti-mouse CD135 Antibody, 50μg

CD135, also known as Flk-2, Flt3, and Ly-72, is a type III tyrosine kinase receptor. It is expressed on early B lymphoid lineage cells in bone marrow, on primitive myeloid progenitors within the BM CD34+ cell population. Ligation of Flk-2 with Flt3 ligand regulates the growth of hematopoietic stem cells and promotes the survival of primitive hematopoietic progenitor cells with myeloid as well as B lymphoid potential. It was reported that the receptor tyrosine kinase Flt3 is required for dendritic cell development. Combined signaling through interleukin-7 receptors and Flt3 selectively promotes B-cell commitment and differentiation from uncommitted murine bone marrow progenitor cells.
50μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Mouse Flt3 transfected cell line
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser: Blue Laser (488 nm)Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application References(PubMed link indicates BioLegend citation): Sergejeva S, et al. 2004. Blood 103:1270. Auffray C, et al. 2009. J. Exp. Med. 206:595. Chiba H, et al. 2013. Am J Physiol Cell Physiol. 305:693. PubMed
Product Citations: Hou X, et al. 2020. Cell Reports. 28(1):172-189.e7.. PubMed Turecamo SE, et al. 2018. Matrix Biol. 67:01:00. PubMed Delbridge AR, et al. 2017. Cell Death Dis. 8:e2914. PubMed Sanmarco LM, et al. 2022. Nature. 611:801. PubMed Rundberg Nilsson A, et al. 2023. iScience. 26:106341. PubMed Lawson H, et al. 2021. Stem Cell Reports. 16:2784. PubMed Wang D, et al. 2022. Cell Rep. 39:110587. PubMed Safi F 2023. STAR Protocols. 4(1):101965. PubMed Gonçalves R, et al. 2023. iScience. 26:105972. PubMed Domingues AF, et al. 2020. Elife. 9:e51754. PubMed Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed Hu X, et al. 2016. Nat Commun. 7:13095. PubMed Riether C, et al. 2021. Cell Reports. 34(4):108663. PubMed Dave K et al. 2017. eLife. 6 pii: e23382. PubMed Dey A et al. 2019. The EMBO journal. 38(7) pii: e100293. PubMed Nakamura‐Ishizu A et al. 2018. Cell reports. 25(7):1772-1785 . PubMed Kurkewich J, et al. 2016. PLoS One. 11: 0161468. PubMed Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed Wang L, et al. 2021. Cancer Immunol Res. 9:348. PubMed Carpenter RS, et al. 2020. Nat Commun. 3.029166667. PubMed JI B, et al. 2016. Cell Death Differ. 23:759-75. PubMed Di Genua C, et al. 2020. Cancer Cell. 37(5):690-704.e8.. PubMed Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed Kinkel SA, et al. 2022. iScience. 25:104684. PubMed Derecka M, et al. 2020. Nat Immunol. 261:21. PubMed Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed Booth CAG, et al. 2018. Cancer Cell. 33:274. PubMed Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed Zhang H, et al. 2019. Mol Cell. 76:110. PubMed Qian J, et al. 2021. Int J Mol Sci. 22:. PubMed Kubota S, et al. 2019. Nat Commun. 10:1653. PubMed Chen Z, et al. 2019. J Exp Med. 216:152. PubMed Fang H, et al. 2020. Nat Commun. 4.661805556. PubMed Balzano M et al. 2019. Cell reports. 26(12):3257-3271 . PubMed Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed Di Genua C, et al. 2019. Haematologica. 104:2215. PubMed Sabnis A, et al. 2009. PLoS One. 7:e59. PubMed Kim SK, et al. 2018. Genes Dev. 32:849. PubMed van den Berk P, et al. 2020. Cell Rep. 33:108533. PubMed Viaud M, et al. 2020. Cell Reports. 30(10):3397-3410. PubMed Schnoegl D, et al. 2022. Front Immunol. 13:909270. PubMed Jackson JT, et al. 2018. Blood Adv. 2:347. PubMed Rivera CA, et al. 2022. Immunity. 55:129. PubMed Dingler FA, et al. 2020. Mol Cell. . PubMed Giotopoulos G, et al. 2015. J Exp Med. 212: 1551-1569. PubMed Yáñez A et al. 2017. Immunity. 47(5):890-902 . PubMed Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
RRID: AB_1877218 (BioLegend Cat. No. 135305) AB_1877217 (BioLegend Cat. No. 135306)
Structure: A 135-150 kD molecule belonging to the tyrosine kinase receptor family.
Distribution: Expressed on early B lymphoid lineage cells in juvenile and adult bone marrow, primitive myeloid progenitors within the BM CD34+ cell population.
Function: Regulate the growth of hematopoietic stem cells and promote the survival of primitive hematopoietic progenitor cells.
Ligand/Receptor: Flk-2/FLT3 ligand
Cell Type: B cells, Hematopoietic stem and progenitors
Biology Area: Immunology
Molecular Family: CD Molecules
Antigen References: 1. Waskow C, et al.Nat. Immunol. 9:676 2. Veiby OP, et al. 1996. Blood 88(4):1256 3. Veiby OP, et al. 1996. J. Immunol. 157(7):2953 4. Mattews W, et al. 1991. Cell. 65(7):1143 5. Hannum C, et al. 1994. Nature 368(2):643 6. Ogawa M, et al. 1998. Exp Hematol. 26(6):478
Gene ID: 14255
UniProt: View information about CD135 on UniProt.org
Clone: A2F10
Regulatory Status: RUO
Other Names: Flk-2, Flt3, Ly-72
Isotype: Rat IgG2a, κ
Q: What type of PE do you use in your conjugates?
A: We use R-PE in our conjugates.